Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. reports developments in sleep health, respiratory care and home healthcare technology. The company supplies sleep apnea and breathing-care devices, including CPAP platforms such as AirSense 11, and supports them with cloud-connected software, AI-enabled digital health tools and patient data applications used in out-of-hospital care.
Recurring updates include quarterly operating results, demand trends for sleep and respiratory care products, FDA-cleared digital medical devices such as Smart Comfort, supply-chain and distribution capacity, shareholder returns, executive leadership changes and investor conference presentations. ResMed’s announcements also reflect its NYSE-listed common stock and ASX-traded presence.
Resmed (NYSE:RMD) has completed its acquisition of Noctrix Health, a wearable-therapeutics company for chronic neurological disorders. The deal adds Noctrix’s Nidra TOMAC Therapy, an FDA De Novo classified, non-invasive, non-pharmacologic treatment for moderate-to-severe Restless Legs Syndrome (RLS), to Resmed’s clinical sleep health portfolio.
Noctrix becomes a wholly owned Resmed subsidiary, supporting Resmed’s 2030 strategy by expanding into RLS, the third most prevalent sleep disorder, with a clinically validated therapy backed by 10 peer-reviewed publications and inclusion in AASM clinical practice guidelines.
Resmed (NYSE:RMD) announced that chairman and CEO Mick Farrell and CFO Aaron Bloomer will participate in the 46th Annual William Blair Growth Stock Conference in Chicago on June 2, 2026. A live, audio-only webcast starts at 4:40 p.m. CT, with a replay available for 90 days.
Resmed (NYSE:RMD) and Oura announced a partnership to expand access to sleep health education and care pathways for Oura Ring members in the U.S.
Oura Ring Gen3 and Ring 4 users with active memberships can access Resmed educational tools, sleep assessments, and options to connect with independent healthcare providers.
Resmed (NYSE: RMD) announced that CFO Brett Sandercock will retire effective May 4, 2026, and Aaron Bloomer will succeed him as CFO. Sandercock will advise the CEO through end of 2027. The company reiterated fiscal 2026 outlook: gross margin 62–63%, SG&A 19–20%, R&D 6–7%, effective tax rate 21–23%.
Resmed (NYSE: RMD) reported Q3 FY2026 results for the quarter ended March 31, 2026: revenue $1.431B (up 11% reported, 8% constant currency), GAAP gross margin 62.2% (+290 bps), GAAP diluted EPS $2.74 and non-GAAP diluted EPS $2.86 (+21%).
Operating cash flow was $554M; the company returned $262M to shareholders via $175M buybacks and $87M dividends, and declared a quarterly dividend of $0.60 per share.
Resmed (NYSE: RMD) will report third quarter fiscal 2026 results on Thursday, April 30, 2026 after the NYSE close and will host a management webcast at 1:30 p.m. PT / 4:30 p.m. ET.
The live webcast is available at https://investor.resmed.com, with replay accessible about two hours after the presentation; phone replay runs April 30–May 14, 2026.
Resmed (NYSE: RMD) released its 2026 Global Sleep Survey of 30,000 people across 13 countries, finding strong awareness but limited action on sleep health.
Key findings: 53% rank sleep the top health behavior, 84% link sleep to longevity, wearable sleep tracking rose to 53%, yet only 23% sought medical help for ongoing issues despite 66% saying they would.
Resmed (NYSE: RMD) will open a new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027. The facility is expected to employ more than 100 full-time and contingent workers and will complement centers in Atlanta and Moreno Valley.
The Greenwood hub will raise two-day transit coverage across North America from 75% to 90% and shorten deliveries to Canada by one day, strengthening U.S. distribution capacity and local job creation.
Resmed (NYSE: RMD) reported Q2 FY2026 results for the quarter ended December 31, 2025: revenue $1.423B (+11% YoY; +9% constant currency), gross margin 61.8% (+320 bps), GAAP diluted EPS $2.68 and non-GAAP diluted EPS $2.81 (+16% non-GAAP). Operating cash flow was $340M. The company paid in dividends, repurchased 704,000 shares for $175M, and declared a quarterly dividend of $0.60 per share.
Management cited manufacturing and logistics efficiencies, component cost improvements, and ongoing investment in digital health and the VirtuOx acquisition as drivers of performance.
Resmed (NYSE: RMD) will report second quarter fiscal 2026 financial and operational results on Thursday, January 29, 2026 after NYSE close. Management will host a live webcast discussing results and other forward-looking material at 1:30 p.m. PST / 4:30 p.m. EST (International: London 9:30 p.m. GMT; Sydney Jan 30 8:30 a.m. AEDT).
The webcast is available only at https://investor.resmed.com. A replay will be posted ~two hours after the webcast; a phone replay is available ~three hours after the webcast through February 12, 2026 (Conference ID: 13757750).